The rationale behind OncoSec Medical using this system is discussed in a Dawson James report.
In a Nov. 25 research note, Dawson James analyst Jason Kolbert reported that OncoSec Medical Inc. (ONCS:NASDAQ) licensed the rights to the Cliniporator gene delivery platform and will use and evaluate it, having already received U.S. Food and Drug Administration (FDA) approval to do so, in an upcoming COVID-19 trial.
In this Phase 1 study, to be held at Providence Health, OncoSec's DNA-encodable COVID-19 vaccine candidate, CORVax12, will be assessed. CORVax12, Kolbert relayed, is a combination of OncoSec's TAVO, short for tavokinogene telseplasmid, and the National Institutes of Health's SARS-CoV-2 virus spike protein.
"CORVax12 may produce a stronger, longer-lasting immune response and, as such, provide enhanced protection against COVID-19 and other viruses, too," Kolbert commented, adding, "Why is this so important? Consider the patient populations at risk. The elderly and immune-compromised may not be capable of mounting an adequate immune response."
For cancer patients, the goal is of TAVO is to "reverse resistance in patients receiving checkpoint therapies. TAVO, which is plasmid-based interleukin-12, is administered locally via OncoSec's electroporation gene delivery system. TAVO induces the local expression of interleukin-12, turning 'cold' tumors 'hot'and enabling checkpoint therapies such as Keytruda (pembrolizumab) to be effective," explained Kolbert.
The analyst discussed the reasons why OncoSec has licensed and is moving forward with IGEA Clinical Biophysics' Cliniporator.
The platform employs low voltage and longer pulses, which is more desirable for delivering DNA vaccines than a system employing high voltage and shorter pulses. Additionally, OncoSec management has come to believe that using Cliniporator to internally deliver TAVO to lung and liver cancer targets may be more effective than using its own investigative visceral lesion applicator (VLA). It bases this on data from its VLA program.
Another factor in OncoSec favoring the Cliniporator is time saved. For one, the biotech already has the green light from the FDA to use it in the CORVax12 trial. Two, the Cliniporator already has a CE Mark, which should accelerate the time required to get into the clinic.
Dawson James has a $10 per share price target on OncoSec Medical, the stock of which is currently trading at about $5.46 per share.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures for Dawson James Securities, OncoSec Medical Inc., November 25, 2020,
The Firm does not make a market in the securities of the subject Company (s). The Firm has NOT engaged in investment banking
relationships with ONCS in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject Company (s). The Firm has NOT received any other compensation from the subject Company (s) in the last 12 months for services unrelated to managing or co-managing of a public offering.
Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or
advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of October 31, 2020, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.
Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the
analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation
that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad
pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.
Analyst Certification: The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analysts compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.